Clinical features and immunohistochemistry profile of biopsy-proven gastric gastrointestinal stromal tumor (GIST): a description of 5 years case series and literature review of GIST
, , , , e
10 set 2020
INFORMAZIONI SU QUESTO ARTICOLO
Categoria dell'articolo: Brief communication (original)
Pubblicato online: 10 set 2020
Pagine: 111 - 117
DOI: https://doi.org/10.1515/abm-2020-0017
Parole chiave
© 2020 Chuthamas Ongprakobkul et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1
Figure 2
Figure 3
Figure 4
Immunohistochemistry study of patients
| 1 | Positive | Positive | Positive | Positive | Positive | |||
| 2 | Positive | Positive | Positive | Negative | Positive | |||
| 3 | Positive | Positive | Positive | Negative | Negative | |||
| 4 | Negative | Negative | Negative | Negative | Positive | Positive | Positive | |
| 5 | Positive | Positive | Negative | Negative | Positive | Negative | ||
| 6 | Positive | Positive | Negative | Negative | ||||
| 7 | Positive | Negative | ||||||
| 8 | Positive | Positive | Negative | Negative | ||||
| 9 | Positive | Positive | Positive | Negative | Negative | Positive | ||
| 10 | Positive | Positive | Positive | |||||
| 11 | Positive | |||||||
| 12 | Positive | Negative | Negative | Negative | Negative | Negative | Positive | |
| 13 | Positive | Positive | Positive | Negative | Negative | Negative | ||
| 14 | Positive | Positive | Positive | Negative | ||||
| 15 | Positive | Positive | Positive | |||||
| 16 | Positive | Positive | Positive | |||||
| 17 | Positive | Positive | Positive | Negative | Negative | Negative | Positive | |
| 18 | Positive | Positive | Positive | Negative | Negative | |||
| 19 | Positive | |||||||
| 20 | Positive | Positive | Positive | Negative | Negative | Negative | Positive | |
| 21 | Positive | Positive | Positive | Negative | Negative | Negative | Positive | Positive |
| 22 | Positive | Positive | Negative | Positive |
Baseline characteristics, tumor locations, size, mitotic rate of tumors, HP test, treatment, and outcome
| 1 | Male | 86 | Cardia | N/A | N/A | Pos | None | DOD |
| 2 | Male | 68 | Body | 7.0 | 4 | N/A | Surgery | NED |
| 3 | Female | 67 | Cardia | 2.4 | 1 | Pos | Surgery | LDP |
| 4 | Female | 42 | Cardia | 4.5 | 1 | N/A | Surgery | NED |
| 5 | Female | 49 | Cardia | 1.5 | 1 | N/A | Surgery | NED |
| 6 | Male | 46 | N/A | 2.1 | 10 | N/A | Surgery | NED |
| 7 | Female | 72 | Antrum | 2.7 | 2 | Neg | Surgery | NED |
| 8 | Female | 54 | Body | 3.4 | 3 | N/A | Surgery | NED |
| 9 | Female | 59 | Body | 4.0 | <5 | N/A | Surgery | NED |
| 10 | Female | 69 | Cardia | 5.0 | 2 | N/A | Surgery | NED |
| 11 | Female | 42 | Fundus | 2.2 | 1 | N/A | Surgery | NED |
| 12 | Male | 71 | Fundus | 4.7 | <5 | N/A | Surgery | NED |
| 13 | Female | 59 | Body | 10.8 | 2 | Neg | Surgery | NED |
| 14 | Female | 60 | Body | 4.5 | 3 | N/A | Surgery | NED |
| 15 | Female | 83 | Body | 2.5 | 4 | N/A | Surgery | NED |
| 16 | Male | 42 | Body | 4.0 | >10 | N/A | Surgery | NED |
| 17 | Male | 44 | Body | 5.0 | 2 | N/A | Surgery | NED |
| 18 | Female | 95 | Body | 5.5 | 4 | Pos | Surgery | NED |
| 19 | Male | 67 | Fundus | N/A | N/A | Pos | CMT | LDP |
| 20 | Female | 74 | Body | N/A | N/A | N/A | CMT | DOD |
| 21 | Male | 68 | Body | 7.5 | 108 | N/A | Surgery + CMT | LDP |
| 22 | Female | 61 | Fundus | 11.0 | 11 | Neg | Surgery + CMT | LDP |